Concepedia

Ole Kleist Jeppesen

OK

Statistics

Publications

16

Citations

5.4K

H-Index

15

Active since

2009

Affiliations

Novo Nordisk (Denmark)(Current)

The University of Texas Southwestern Medical Center

University College London

Pennington Biomedical Research Center

Cleveland Clinic Lerner College of Medicine

Ole Kleist Jeppesen is an author at Novo Nordisk (Denmark) specializing in clinical pharmacology, pharmacotherapy, and pharmacology.

Publications per year

2009–2025

16

Publications

16

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

, , +16

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.3K citations · Full text

, , +10

Once-Weekly Semaglutide in Adolescents with Obesity

Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez et al. · New England Journal of Medicine · 2022 · 638 citations · Full text

, , +15

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al. · Diabetes Care · 2019 · 468 citations · Full text

, , +17

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Donna H. Ryan, Ildiko Lingvay, John Deanfield et al. · Nature Medicine · 2024 · 286 citations · Full text

, , +17

1–5 of 16